1 Medicare Advantage Chronic Care Improvement Program Training for Medicare Advantage Organizations...
-
Upload
spencer-priest -
Category
Documents
-
view
220 -
download
0
Transcript of 1 Medicare Advantage Chronic Care Improvement Program Training for Medicare Advantage Organizations...
1
Medicare Advantage Chronic Care Improvement Program
Training for Medicare Advantage Organizations
Marsha Davenport, MD MPHCAPT, USPHS Chief Medical Officer
and
Karla Taylor, PharmD
Medicare Drug and Health Plan Contract Administration Group
April 11, 2012
2
Presentation Overview: Part I
• QI Program Overview• Background• Million Hearts Campaign• Disease Management• Components of a CCIP• Case Studies• Discussion• Brief break/Stretch
3
Presentation Overview: Part II
• CCIP Reporting process• Plan-Do-Study-Act (PDSA)• CY2011 and CY2012 submissions
• Role of Central Office Quality Team• Role of Regional Office (RO) Account Managers (AM) and
Clinicians• Review CCIP Reporting Tool• Case Studies• Questions and Wrap up
5
Quality Improvement (QI) Program
• 42 Code of Federal Regulations (CFR) § 422.152
• Applies to all MAOs, including SNPs• Seven components of the QI Program• Serves to integrate and coordinate all of the assessment
tools and reporting requirements
6
QI Program -2-
1. Chronic care improvement program (CCIP)• Meet the requirements of 42CFR §422.152(c)• Addresses populations identified by CMS based on review of
current quality performance
2. Quality improvement projects (QIPs)• Meet the requirements of 42CFR §422.152(d)• Expected to have a favorable effect on health outcomes and
enrollee satisfaction• Address areas identified by CMS
7
QI Program -3-
3. Develop and maintain a health information system
4. Encourage providers to participate in CMS and Health & Human Services (HHS) QI initiatives
5. Contract with an approved Medicare CAHPS vendor to conduct the Medicare CAHPS satisfaction survey
8
QI Program -4-
6. Include a program review process for the formal evaluation of the QI Program that addresses at least the following areas on an annual basis:• Impact• Effectiveness
7. Take remedial action to correct problems identified using ongoing quality improvement
11
Background
• Identified need to improve reporting tools for both the CCIPs and the QIPs• Follow the QI cycle of Plan, Do, Study, Act• More focused on interventions and outcomes• Participate in national health initiatives
• CCIPs must be clinical• QIPs may be clinical or non-clinical
12
Background -2-
• CMS is involved in several important Department of Health and Human Services (HHS) Initiatives
• Want to ensure that our beneficiaries enrolled in the Medicare Advantage (MA) program have the opportunity to benefit from these initiatives
13
Background -3-
• The required topic for the CY 2012 CCIPs is reducing risks for cardiovascular disease
• This topic is the focus of the national Million Hearts Campaign
14
Background -4-
• The required topic for the CY 2012 QIPs is decreasing plan all cause readmissions
• Current HEDIS® measure• One of the goals of the national CMS Partnership for Patient
Initiative
16
Heart Disease and Strokes
• Also referred to has cardiovascular disease (CVD)• Over 2 million heart attacks and strokes each year• Leading killers in the U.S.
• Cause 1 of every 3 deaths ~ 800,000 deaths• Leading cause of preventable death in people < 65
Source: Million Hearts Campaign 2012
17
Heart Disease and Strokes -2-
• Billions of dollars (~ $444 ) in health care costs and lost productivity
• Treatment accounts for ~ $1 of every $6 spent• Greatest differences in racial disparities for life expectancy
Source: Million Hearts Campaign 2012
18
CVD Leading Cause of Shorter Life Expectancy Among African Americans
Source: Million Hearts Campaign 2012
19
Improving CVD Care
• Aspirin• Blood pressure• Cholesterol• Smoking
Source: Million Hearts Campaign 2012
20
Status of the ABCS
Aspirin People at increased risk of cardiovascular disease who are taking aspirin
47%
Blood pressure
People with hypertension who have adequately controlled blood pressure
46%
Cholesterol People with high cholesterol who have adequately controlled hyperlipidemia
33%
Smoking People trying to quit smoking who get help 23%
Source: Million Hearts Campaign 2012
21
Million Hearts Outcomes
• 10M more people with HBP controlled• 20M more people with high
cholesterol controlled• 4M fewer people will smoke • 20% drop in average sodium intake• 50% drop in average trans fat intake
Source: Million Hearts Campaign 2012
22
Key Components of Million Hearts
Community Prevention• Reduce the number of people who need treatment
Clinical Prevention• Optimize care for those people who do need treatment
Source: Million Hearts Campaign 2012
23
Medical System Messages
• Clinicians • Emphasize power of prevention• Create systems to get an “A” in the ABCS• Use decision supports and registries to drive performance• Deploy teams
• Pharmacists• Monitor and influence refill patterns• Work in teams• Teach adherence
Source: Million Hearts Campaign 2012
24
Medical System Messages -2-
• Insurers • Measure and incentivize performance on the ABCS; collect
and share data for quality improvement; empower consumers
• Individuals • Know your numbers—and goals • Take aspirin, if advised • Get aggressive with BP and Cholesterol• Cut sodium and trans fats• If you smoke, quit
Source: Million Hearts Campaign 2012
25
Community Messages -2-
• Retailers and Employers• Offer blood pressure monitoring and educational resources• Focus on improving ABCS care in retail and worksite clinics
• Advocacy groups • Monitor and demand progress toward goal• Promote actions that prevent heart attacks and strokes
Source: Million Hearts Campaign 2012
26
Community Messages
• Government • Support community and systems transformation to reduce
tobacco use and improve nutrition• Provide data for action
• Foundations • Support consumer and provider outreach and activation
Source: Million Hearts Campaign 2012
27
Million Hearts: Getting to the Goal
Population metric Baseline 20171 Clinical target2
Aspirin for those at high risk ~50% 65% ~70%
Blood pressure control ~50% 65% ~70%
Cholesterol control ~33% 65% ~70%
Smoking prevalence ~20% 17% ─
Average sodium intake 3.5g/day 20% ↓ ─
Average artificial trans fat intake 1% of calories/day 50% ↓ ─
1 Population-wide indicators2 Clinical systems
Source: Million Hearts Campaign 2012
30
What is Disease Management?
• Supports physician/patient plan of care• Emphasis on prevention• Outcomes evaluated continuously
31
What Can Disease Management Do?
• Improve safety and quality of care• Improve access to care• Improve patient self-management• Decrease costs • Provide health improvement based on plan on population
32
Disease State Selection
• Determine incidence and prevalence• Identify data sources• What data do I have to use to track and monitor progress for
the patients• Is the disease relevant to the patients• Are there gaps in the current program
33
Disease State Selection -2-
• Is the disease clinically manageable• What is the current impact for the MA plan members• Will changing how the disease is managed have a positive
impact
34
Disease Management: Six Required Elements
• Population identification• Evidence based guidelines• Collaborative care• Patient self-management• Process and outcome measures• Routine reporting/feedback loop
36
Evidence Based Guidelines
• Set of actions based on clinical research• Effectively manage or improve outcomes• Ensures consistency in treatment
37
Collaborative Care Model
• Structured interdisciplinary team• Patient centered CCIP• Designed to provide best possible outcomes
38
Patient Self-Management
• Systematic provision of education and supportive interventions
• Increase patient skills and confidence in managing their health
39
Process and Outcome Measures
• Determines program stability• Reflects the impact on health status of the targeted
population
40
Routine Reporting/Feedback Loop
• Process of communication • Keeps all care team members and patient in the loop
42
Required CCIP Disease Selection
• New for 2012• Cardiovascular Disease focus• Must still be individualized to meet the needs of the MA
plan’s population
43
Components of the CCIP
• Disease state selection• Six disease management elements• Anticipated outcomes• Goal(s)• Interventions
44
Anticipated Outcomes
• Determining what the program will achieve• Must positively improve health outcomes• Important factor in evaluation of the CCIP
45
Goals
• Relevant to the program• Specific• Measureable• Positive effect on health outcomes• Attainable
46
Interventions
• Relates to the both the disease state selected and the goals• Designed to reach the goal• Some questions to consider• Can this intervention improve health outcomes• Can the impact of the intervention be measured• Is the intervention sustainable
48
Case Study #1: Diabetes
• Develop a Diabetes CCIP• Walk through the components of the CCIP• Provide specific examples for disease management
elements and the CCIP components
55
Plan-Do-Study-Act (PDSA) Quality Model
• Plan
Identify disease state, plan the program• Do
Implementation of the program• Study
Data collection and analysis• Act
Next Steps
57
CY 2011 CCIP Submissions
• The CCIPS submitted later this Spring are based on what health plans worked on in CY 2011
• Will report using the new templates• Submitted from May 1-15, 2012• CCIPs will be scored by a contractor• New HPMS module• Training on HPMS module in late April
58
CY 2012 CCIP Submissions
• Submitted in two sections• Plan section due June 11-July 31• Do-Study-Act sections will be required to be submitted in early
2013
• MAOs must work with the AMs to have the Plan section approved
• Cannot begin CCIP without the AM’s approval• Completed within HPMS using new template
60
Regional Office (RO) Account Managers (AMs)
• Will provide day-to day monitoring of the QI Program• Provide technical assistance (TA) to health plans to improve
their overall QI program• Review and approve the Plan Sections of the CCIPs and the
QIPs
63
A. Basis for Selection
• A1. Disease State (not scored)• A2. Rationale for Selection• A3. Relevance to the Plan Population• A4. Anticipated Outcomes
64
A2. Rationale for Selection
• The rationale for selecting the specific disease state• How the data sources showed the gap in the current care
that confirms the need for a specialized program• Incidence and/or prevalence of the disease within the MA
Plan population supported by the data sources
65
A3. Relevance to the Plan Population
• How the program is relevant to the MA Plan population through incidence and/or prevalence of the disease
• The impact the disease currently has on the members• How filling the gap in care identified in A2 will improve health
outcomes
66
A4. Anticipated Outcomes
• The expected outcome of the program• How the members will be impacted by the outcome• A brief description of the evidence based guidelines
considered and how these will be effective in producing improved health outcomes
67
A5. Data Sources
• Section is not scored but critical to the development of the CCIP
• MAOs may chose to use data sources other than the ones listed in the CCIP reporting tool
• Incorporate information from as many of the data sources that make sense into the CCIP
• Understand the link between the data and the CCIP
68
B. Program Design
• B1. Population Identification Process• B1(a). Describe the Target Population• B1(b). Method of identifying members (not scored)• B1(c). Risk Stratification (not scored)• B1(d). Enrollment method (not scored)
69
B. Program Design -2-
• B2. Evidence Based Medicine• B3. Care Coordination Approach• B4. Education
• B4(a). Patient Self-Management• B4(b). Provider Education
70
B. Program Design -3-
• B5. Outcome Measures and Interventions• B(5a). Goal• B5(b). Benchmark• B5(c). Goal and Benchmark indicators• B5(d). Intervention
71
B. Program Design -4-
• B5. Outcome Measures and Interventions (cont’d)• B5(e). Rationale for specific intervention related to goal or
benchmark• B5(f). Measurement Methodology• B5(g)Timeline
• B6. Communication Sources (not scored)
72
B1. Population Identification Process
• B1(a): Describe the target population • Inclusion criteria• Exclusion criteria• Incidence rate among the members related to the inclusion
criteria
73
B1. Population Identification Process -2-
• B1(a): Describe the target population (cont’d)• The illness severity level of the members included• The demographics and clinical variables used to identify
members appropriate for inclusion in the program
74
B2. Evidence Based Medicine
• The evidence based medical guidelines chosen from a credible and authoritative institution
• Why the guidelines were chosen including how their use will impact health outcomes
75
B2. Evidence Based Medicine -2-
• How the guidelines will be applied to the program including • How they will be applied across different demographics
and• Different illness severity levels (with an example
provided)
• The source and date of the guidelines
76
B3. Care Coordination Approach
• The internal and external team members• The team’s approach for the program• The roles and responsibilities of the team members• The model of care (MOC) or care plan• Culturally competent care
77
B3. Care Coordination Approach -2-
• How the team will communicate and work together to support the member and the goal (with an example)
• How the individual member’s goals and outcomes will be assessed and addressed with an example provided
78
B4(a). Education: Patient Self-Management
• Description of the planned methods and educational topics used for training, support, monitoring, and follow-up of members
• The methods are varied and take into consideration the different demographics, socioeconomic status, and cultural backgrounds of the members
79
B4(a). Education: Patient Self-Management -2-
• The educational topics that support improvement in health outcomes and are designed for different acuity levels, demographics, socioeconomic status and cultural backgrounds of the members
• Training, support, monitoring, and follow up are addressed
80
B4(b). Education: Provider Education
• Provider training on the applicable evidence based guidelines for the identified condition
• Methods for providing appropriate support for the members in managing their condition and monitoring of the member
• Methods and frequency for follow up of the member
81
B5(a). Goal
• A goal that is specific and relevant to the program• The evidence or factors considered that show how
achieving the goal will impact health outcomes• How the goal is measureable and attainable in the set
timeframe
82
B5(b). Benchmark
• A valid, reliable benchmark that is relevant to the goal of the program
• How it relates to the demographics of the target population• How use of it reflects the complexity of the disease state the
program is targeting• The current date of the benchmark
83
B5(d). Intervention
• The planned intervention• How it is measureable and capable of effecting improved
health outcomes• How the intervention relates to the goal • How it is sustainable over time
84
B5(e). Rationale for Specific Intervention
• The reason the intervention was chosen• How it relates to the goal and benchmark• The factors or evidence considered when developing the
intervention that demonstrates its validity • How health outcomes are anticipated to be impacted
85
B5(f). Measurement Methodology
• The specific valid and reliable data that will be collected for measurement
• How the measure relates to the intervention, the goal, and the benchmark
• The systematic method in which that data will be collected• Frequency of data collection and analysis
86
B5(g). Timeline
• Exact beginning and ending dates for the measurement cycle
• An explanation of how the timeline reflects an appropriate amount of time to complete the planned intervention
• The rationale for the expected timeline
88
E. Program Implementation, Review, Revision
• E1. Education• E1(a). Patient Self-Management• E1(b). Provider Education
• E2. Intervention• E3. Results or Findings• E4. Barriers Encountered• E5. Mitigation Plan for Risk Assessment• E6. Anticipated Impact on the Goal and/or Benchmark
90
F. Results
• F1. Goal• F2. Benchmark• F3. Timeline• F4. Dates of Implementation• F5. Sample Size or Percent of Total Population
91
F. Results -2-
• F6. Numerator• F7. Denominator• F8. Total Percent or Results• F9. Other Data or Results• F10. Analysis of Results or Findings
93
G. The Next Steps
• G1. Continue the program with no changes• G2. Continue the program with changes• G3. Develop a QIP to study one or more aspects of the
program• G4. Discontinue the program• G5. Re-evaluate and change the goal or benchmark
selected
94
G. The Next Steps -2-
• G6. Expand the program• G7. Identify additional interventions• G8. Re-evaluate data and criteria• G9. Other
96
Summary
• Identify requirements of QI Program and CCIPs• Explain how CCIPs improve health outcomes and quality of
care• Describe disease management • Understand the CCIP Reporting Tool
98
Disease Management and the CCIP Reporting tool
• Population identification• Plan sections A1-4• Plan section B1
• Evidence based guidelines• Plan section B2
• Collaborative Care• Plan section B3
99
Disease Management and the CCIP Reporting tool -2-
• Patient self-management• Plan section B4(a)• Do section E1(a)
• Process and outcomes measures• “Plan” section B5• “Do” section E3• “Study” section
• Reporting and feedback loop• “Act” section
100
Case Study #1: Diabetes
• Develop a Diabetes CCIP• Walk through the components of the CCIP• Provide specific examples for disease management
elements and the CCIP components
104
Contact Information
Marsha Davenport, MD, MPH
CAPT, USPHS
Chief Medical Officer
Medicare Drug and Health Plan Contract Administration Group (MCAG)
410-786-0230